Tipranavir
This antiretroviral medication is a protease inhibitor used as part of combination therapy to treat HIV infection in adults and children who have already been treated with other HIV medications and whose virus has become resistant to them. It must always be combined with a low dose of ritonavir to reach effective blood levels. Serious liver toxicity can occur, so liver function must be carefully monitored.
分子量
602.7000 g/mol
LogP
7.00
TPSA
114.00 Ų
リピンスキーの五則
不適合
治療領域
作用機序
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
2D構造
Cite this structure
Embed this structure
SMILES
CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1
InChI
InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1
Molecular Formula
C31H33F3N2O5S
HBD / HBA
2 / 10
回転可能結合数
11
重原子数
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
This antiretroviral medication is a protease inhibitor used as part of combination therapy to treat HIV infection in adults and children who have already been treated with other HIV medications and whose virus has become resistant to them. It must always be combined with a low dose of ritonavir to reach effective blood levels. Serious liver toxicity can occur, so liver function must be carefully monitored.
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.
Yes, Tipranavir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL222559. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54682461. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tipranavir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tipranavir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tipranavir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tipranavir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tipranavir"></drugfyi-drug>